The exploration of cancer vaccines utilizing peptides presented by MHC-I molecules of dendritic cell for CD8 T-cell activation has been persistently advanced, stimulated by the successes of T-cell therapies, coupled with the growing interest in personalized mutant antigens [96,97]. Here, CD8A is linked to cancer.